Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial | |
Qin, Shukui; Li, Jin; Wang, Liwei; Xu, Jianming; Cheng, Ying; Bai, Yuxian; Li, Wei; Xu, Nong; Lin, Li-zhu; Wu, Qiong | |
刊名 | JOURNAL OF CLINICAL ONCOLOGY
![]() |
2018 | |
卷号 | 36期号:30 |
ISSN号 | 0732-183X |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3416484 |
专题 | 昆明医科大学 |
推荐引用方式 GB/T 7714 | Qin, Shukui,Li, Jin,Wang, Liwei,et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial[J]. JOURNAL OF CLINICAL ONCOLOGY,2018,36(30). |
APA | Qin, Shukui.,Li, Jin.,Wang, Liwei.,Xu, Jianming.,Cheng, Ying.,...&Liu, Tianshu.(2018).Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.JOURNAL OF CLINICAL ONCOLOGY,36(30). |
MLA | Qin, Shukui,et al."Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial".JOURNAL OF CLINICAL ONCOLOGY 36.30(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论